Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Boe Sandahl Sørensen"'
Autor:
Jesper Geert Pedersen, Mateo Sokac, Boe Sandahl Sørensen, Adam Andrzej Luczak, Ninna Aggerholm-Pedersen, Nicolai Juul Birkbak, Trine Heide Øllegaard, Martin Roelsgaard Jakobsen
Publikováno v:
Cancers, Vol 14, Iss 14, p 3342 (2022)
Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding long-term survival in a considerable proportion of the patients. Yet, 40–60% of patients do not achieve a long-term benefit from such therapy, emph
Externí odkaz:
https://doaj.org/article/2ba2d25f6c834ae1ad9e3c40fa2b588b
Autor:
Jesper Geert Pedersen, Anne Tranberg Madsen, Kristine Raaby Gammelgaard, Ninna Aggerholm-Pedersen, Boe Sandahl Sørensen, Trine Heide Øllegaard, Martin Roelsgaard Jakobsen
Publikováno v:
Cancers, Vol 12, Iss 6, p 1414 (2020)
Purpose: Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40–60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune checkpoint in
Externí odkaz:
https://doaj.org/article/7f5ac354b04941ada27d385073fc27de
Autor:
Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen, Odd Terje Brustugun
Publikováno v:
Eide, I J Z, Stensgaard, S, Helland, Å, Ekman, S, Mellemgaard, A, Hansen, K H, Cicenas, S, Koivunen, J, Grønberg, B H, Sørensen, B S & Brustugun, O T 2022, ' Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations : a post-hoc subgroup analysis with pooled data from two phase II clinical trials ', Translational Lung Cancer Research, vol. 11, no. 6, pp. 953-963 . https://doi.org/10.21037/tlcr-21-995
Translational Lung Cancer Research (TLCR)
Translational Lung Cancer Research (TLCR)
Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 is largely unknown. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf92d28602e537f5a1f22275cc40a2cd
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
Autor:
Sara Bønløkke, Torben Steiniche, Boe Sandahl Sorensen, Gitte‐Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakær, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Magnus Stougaard
Publikováno v:
Molecular Oncology, Vol 18, Iss 5, Pp 1231-1244 (2024)
For cervical cancer (CC), circulating cell‐free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load and survival. In this study, pre‐treatment plasma from 139 CC cases (50 primary surger
Externí odkaz:
https://doaj.org/article/ff0349f899b14681a67f3aa4b23c11ad
Autor:
Inger Johanne Zwicky, Eide, Simone, Stensgaard, Åslaug, Helland, Simon, Ekman, Anders, Mellemgaard, Karin Holmskov, Hansen, Saulius, Cicenas, Jussi, Koivunen, Bjørn Henning, Grønberg, Boe Sandahl, Sørensen, Odd Terje, Brustugun
Publikováno v:
Translational lung cancer research. 11(6)
Osimertinib is standard of care forWe identified patients with uncommonOf 299 enrolled patients in the two trials, 21 patients with uncommon mutations were identified; 12 patients had a single mutation (G719X or L861Q), one patient had L861Q and an e
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100802- (2024)
Background: Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy of progressing patients. However, the
Externí odkaz:
https://doaj.org/article/3df6c84844b845c8b2c5af5bcd5540bc
Autor:
Christoffer Trier Maansson, Peter Meldgaard, Magnus Stougaard, Anders Lade Nielsen, Boe Sandahl Sorensen
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 722-736 (2023)
Cell‐free DNA (cfDNA) in blood plasma can be bound to nucleosomes that contain post‐translational modifications representing the epigenetic profile of the cell of origin. This includes histone H3 lysine 36 trimethylation (H3K36me3), a marker of a
Externí odkaz:
https://doaj.org/article/d4898b4fdb484ec09ae806f348de054c
Autor:
Christoffer Trier Maansson, Emma Roger Andersen, Maiken Parm Ulhoi, Peter Meldgaard, Boe Sandahl Sorensen
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background EML4-ALK gene fusions are oncogenic drivers in non-small cell lung cancer (NSCLC), and liquid biopsies containing EML4-ALK fragments can be used to study tumor dynamics using next-generation sequencing (NGS). However, the sensitiv
Externí odkaz:
https://doaj.org/article/cc429b21f99f4197bc0eaf3a0f475651
Publikováno v:
Thune Mouritzen, M, Carus, A, Meldgaard, P, Sørensen, B S & Hager, H 2018, ' Nye biomarkører for behandling med immun checkpoint inhibitorer ved avanceret ikke-småcellet lungekræft ', Dansk Selskab for Klinisk Onkologi Årsmøde 2018, Nyborg, Danmark, 12/04/2018-14/04/2018 .
Aalborg University
Thune Mouritzen, M, Hager, H, Sørensen, B S, Meldgaard, P & Carus, A 2018, Nye biomarkører for behandling med immun checkpoint inhibitorer ved avanceret ikke-småcellet lungekræft . i Danske Kræftforskningsdage : Abstract Book ., #99, s. 107, Danske Kræftforskningsdage 2018, Odense, Danmark, 30/08/2018 .
Aalborg University
Thune Mouritzen, M, Hager, H, Sørensen, B S, Meldgaard, P & Carus, A 2018, Nye biomarkører for behandling med immun checkpoint inhibitorer ved avanceret ikke-småcellet lungekræft . i Danske Kræftforskningsdage : Abstract Book ., #99, s. 107, Danske Kræftforskningsdage 2018, Odense, Danmark, 30/08/2018 .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::010f8a05f73a34e969cb5bb32100864e
https://vbn.aau.dk/da/publications/5d26d34b-f497-4f1f-8be7-8a0282f08173
https://vbn.aau.dk/da/publications/5d26d34b-f497-4f1f-8be7-8a0282f08173
Autor:
Christoffer Trier Maansson, Louise Skov Thomsen, Peter Meldgaard, Anders Lade Nielsen, Boe Sandahl Sorensen
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 2, p 1243 (2024)
Multiple studies have shown that cell-free DNA (cfDNA) from cancer patients differ in both fragment length and fragment end motif (FEM) from healthy individuals, yet there is a lack of understanding of how the two factors combined are associated with
Externí odkaz:
https://doaj.org/article/3a4abeef169542dc9e08909c8b0adc71